HC Wainwright Reiterates Buy Rating for IceCure Medical (NASDAQ:ICCM)

IceCure Medical (NASDAQ:ICCM)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $2.50 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 125.23% from the company’s previous close.

IceCure Medical Stock Up 0.5 %

ICCM stock opened at $1.11 on Friday. IceCure Medical has a 52 week low of $0.48 and a 52 week high of $1.66. The business has a 50-day simple moving average of $1.32 and a 200 day simple moving average of $0.99. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. The company has a market cap of $61.61 million, a PE ratio of -3.83 and a beta of 0.37.

IceCure Medical (NASDAQ:ICCM) last issued its earnings results on Thursday, March 27th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $1.07 million. IceCure Medical had a negative net margin of 376.85% and a negative return on equity of 124.44%. Sell-side analysts anticipate that IceCure Medical will post -0.28 EPS for the current fiscal year.

Hedge Funds Weigh In On IceCure Medical

A hedge fund recently raised its stake in IceCure Medical stock. Geode Capital Management LLC grew its holdings in shares of IceCure Medical Ltd (NASDAQ:ICCM) by 58.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 40,453 shares of the company’s stock after acquiring an additional 14,893 shares during the quarter. Geode Capital Management LLC owned 0.07% of IceCure Medical worth $44,000 at the end of the most recent quarter. 0.62% of the stock is currently owned by institutional investors and hedge funds.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.